Galena Biopharma (GALE) Shares are Up 1.99%

Galena Biopharma (GALE) has been under a strong bear grip, hence the stock is down -4.72% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.02% in the past 1 week. The stock has risen by 1.99% in the past week indicating that the buyers are active at lower levels, but the stock is down -4.36% in the past 4 weeks.

Galena Biopharma, Inc. has dropped 71.68% during the last 3-month period . Year-to-Date the stock performance stands at -70.72%. The stock has recorded a 20-day Moving Average of 2.55% and the 50-Day Moving Average is 53.35%.


Galena Biopharma (NASDAQ:GALE): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.40 and $0.40 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.45. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.43, notching a gain of 6.80% for the day. The total traded volume was 6,748,003 . The stock had closed at $0.40 on the previous day.

Also, Equity Analysts at the Raymond James downgrades the rating on Galena Biopharma (NASDAQ:GALE). The brokerage firm has issued a Market Perform rating on the shares. The shares were previously rated Outperform. The rating by the firm was issued on June 29, 2016.

Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *